|
71 |
The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis
Enthalten in Bone marrow transplantation Bd. 56, 18.6.2020, Nr. 1, date:1.2021: 30-37
|
|
|
|
72 |
Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
Enthalten in Bone marrow transplantation Bd. 57, 18.8.2022, Nr. 11, date:11.2022: 1664-1670
|
|
|
|
73 |
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
Enthalten in Leukemia Bd. 38, 27.8.2024, Nr. 11, date:11.2024: 2419-2428
|
|
|
|
74 |
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Enthalten in Journal of hematology & oncology Bd. 16, 22.7.2023, Nr. 1, date:12.2023: 1-17
|
|
|
|
75 |
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
Enthalten in Bone marrow transplantation Bd. 59, 15.3.2024, Nr. 7, date:7.2024: 928-935
|
|
|
|
76 |
Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
Enthalten in Current hematologic malignancy reports Bd. 10, 5.2.2015, Nr. 1, date:3.2015: 59-64
|
|
Administration
